{"id": "267223", "url": "https://fevir.net/resources/ResearchStudy/267223", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/study-registry-record"], "versionId": "10", "lastUpdated": "2025-12-11T20:35:21.032Z"}, "name": "NCT03421379_FHIR_Transform", "site": [{"type": "Location", "reference": "#NCT03421379-Location-0"}, {"type": "Location", "reference": "#NCT03421379-Location-1"}, {"type": "Location", "reference": "#NCT03421379-Location-2"}, {"type": "Location", "reference": "#NCT03421379-Location-3"}], "label": [{"type": {"coding": [{"code": "official", "system": "http://hl7.org/fhir/title-type", "display": "Official title"}]}, "value": "A Phase 3 Study of Nasal Glucagon (LY900018) Compared to Intramuscular Glucagon for Treatment of Insulin-induced Hypoglycemia in Japanese Patients With Diabetes Mellitus"}], "phase": {"coding": [{"code": "phase-3", "system": "http://terminology.hl7.org/CodeSystem/research-study-phase", "display": "Phase 3"}]}, "title": "A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus", "citeAs": "A Study of Nasal Glucagon (LY900018) in Japanese Participants With Diabetes Mellitus [Database Entry: FHIR ResearchStudy Resource]. Contributors: Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter [Authors/Creators]. In: Fast Evidence Interoperability Resources (FEvIR) Platform, FOI 267223. Revised 2025-12-11. Available at: https://fevir.net/resources/ResearchStudy/267223. Computable resource at: https://fevir.net/resources/ResearchStudy/267223#json.", "result": [{"type": "Composition", "display": "Results Section for NCT03421379", "reference": "Composition/267224", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379 Results Report", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}], "status": "active", "condition": [{"text": "Diabetes Mellitus"}], "contained": [{"id": "NCT03421379-drug------glucagon-nasal-powder", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "name": "NCT03421379_drug______glucagon_nasal_powder", "note": [{"text": "suggested alternative name: LY900018"}], "title": "Glucagon Nasal Powder", "status": "active", "classifier": [{"text": "Intervention Type: DRUG"}], "description": "Administered intranasally", "resourceType": "EvidenceVariable", "handling": "boolean"}, {"id": "NCT03421379-drug------glucagon-hydrochloride-solution", "meta": {"profile": ["http://hl7.org/fhir/uv/ebm/StructureDefinition/variable-definition"]}, "name": "NCT03421379_drug______glucagon_hydrochloride_solution", "note": [{"text": "suggested alternative name: GlucaGen\u00ae"}], "title": "Glucagon Hydrochloride Solution", "status": "active", "classifier": [{"text": "Intervention Type: DRUG"}], "description": "Administered IM", "resourceType": "EvidenceVariable", "handling": "boolean"}, {"id": "NCT03421379-comparison-group-0", "code": {"text": "Experimental"}, "title": "NCT03421379 Comparison Group: Glucagon Nasal Powder", "status": "active", "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Computable Publishing\u00ae: [System]-to-FEvIR Converter"}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-comparison-group-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "membership": "conceptual", "description": "A single dose of 3 milligram (mg) glucagon nasal powder administered intranasally.", "resourceType": "Group", "characteristic": [{"code": {"text": "Exposed to"}, "exclude": false, "valueReference": {"type": "EvidenceVariable", "display": "Drug: Glucagon Nasal Powder", "reference": "#NCT03421379-drug------glucagon-nasal-powder"}}]}, {"id": "NCT03421379-comparison-group-1", "code": {"text": "Active Comparator"}, "title": "NCT03421379 Comparison Group: Glucagon Hydrochloride Solution", "status": "active", "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Computable Publishing\u00ae: [System]-to-FEvIR Converter"}}], "identifier": [{"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-comparison-group-1", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "membership": "conceptual", "description": "A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM)", "resourceType": "Group", "characteristic": [{"code": {"text": "Exposed to"}, "exclude": false, "valueReference": {"type": "EvidenceVariable", "display": "Drug: Glucagon Hydrochloride Solution", "reference": "#NCT03421379-drug------glucagon-hydrochloride-solution"}}]}, {"id": "NCT03421379-Location-0", "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "address": {"city": "Fukuoka", "country": "Japan", "postalCode": "812-0025"}, "position": {"latitude": 33.6, "longitude": 130.41667}, "resourceType": "Location"}, {"id": "NCT03421379-Location-1", "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "address": {"city": "Tokyo", "country": "Japan", "postalCode": "130-0004"}, "position": {"latitude": 35.6895, "longitude": 139.69171}, "resourceType": "Location"}, {"id": "NCT03421379-Location-2", "name": "For additional information regarding investigative sites for this trial, contact 1-888-545-5972 Mon - Fri, 9 AM to 4 PM or 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri, 9 AM to 5 PM Eastern Time or speak with your personal physician.", "address": {"city": "Tokyo", "country": "Japan", "postalCode": "162-0053"}, "position": {"latitude": 35.6895, "longitude": 139.69171}, "resourceType": "Location"}, {"id": "NCT03421379-Location-3", "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician.", "address": {"city": "Tokyo", "country": "Japan", "postalCode": "169-0073"}, "position": {"latitude": 35.6895, "longitude": 139.69171}, "resourceType": "Location"}], "extension": [{"url": "http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration", "extension": [{"url": "activity", "valueCodeableConcept": {"coding": [{"code": "registration-submission", "system": "http://hl7.org/fhir/research-study-registration-activity", "display": "Registration submission"}]}}, {"url": "actual", "valueBoolean": true}, {"url": "period", "valuePeriod": {"start": "2018-01-30"}}]}, {"url": "http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration", "extension": [{"url": "activity", "valueCodeableConcept": {"coding": [{"code": "results-submission", "system": "http://hl7.org/fhir/research-study-registration-activity", "display": "Results submission"}]}}, {"url": "actual", "valueBoolean": true}, {"url": "period", "valuePeriod": {"start": "2019-08-14"}}]}, {"url": "http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration", "extension": [{"url": "activity", "valueCodeableConcept": {"coding": [{"code": "registration-submission-qc", "system": "http://hl7.org/fhir/research-study-registration-activity", "display": "Registration submission Quality Check"}]}}, {"url": "actual", "valueBoolean": true}, {"url": "period", "valuePeriod": {"start": "2018-01-30"}}]}, {"url": "http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration", "extension": [{"url": "activity", "valueCodeableConcept": {"coding": [{"code": "results-submission-qc", "system": "http://hl7.org/fhir/research-study-registration-activity", "display": "Results submission Quality Check"}]}}, {"url": "actual", "valueBoolean": true}, {"url": "period", "valuePeriod": {"start": "2019-09-18"}}]}, {"url": "http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration", "extension": [{"url": "activity", "valueCodeableConcept": {"coding": [{"code": "record-verification", "system": "http://hl7.org/fhir/research-study-registration-activity", "display": "Record Verification"}]}}, {"url": "actual", "valueBoolean": true}, {"url": "period", "valuePeriod": {"end": "2019-09"}}]}, {"url": "http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration", "extension": [{"url": "activity", "valueCodeableConcept": {"coding": [{"code": "update-submission", "system": "http://hl7.org/fhir/research-study-registration-activity", "display": "Update submission"}]}}, {"url": "actual", "valueBoolean": true}, {"url": "period", "valuePeriod": {"end": "2019-09-18"}}]}, {"url": "http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration", "extension": [{"url": "activity", "valueCodeableConcept": {"coding": [{"code": "registration-posting", "system": "http://hl7.org/fhir/research-study-registration-activity", "display": "Registration posting"}]}}, {"url": "actual", "valueBoolean": true}, {"url": "period", "valuePeriod": {"start": "2018-02-05"}}]}, {"url": "http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration", "extension": [{"url": "activity", "valueCodeableConcept": {"coding": [{"code": "results-posting", "system": "http://hl7.org/fhir/research-study-registration-activity", "display": "Results posting"}]}}, {"url": "actual", "valueBoolean": true}, {"url": "period", "valuePeriod": {"start": "2019-10-08"}}]}, {"url": "http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration", "extension": [{"url": "activity", "valueCodeableConcept": {"coding": [{"code": "primary-outcome-data-collection", "system": "http://hl7.org/fhir/research-study-registration-activity", "display": "Primary outcome data collection"}]}}, {"url": "actual", "valueBoolean": true}, {"url": "period", "valuePeriod": {"end": "2018-08-20"}}]}, {"url": "http://hl7.org/fhir/StructureDefinition/researchStudy-studyRegistration", "extension": [{"url": "activity", "valueCodeableConcept": {"coding": [{"code": "update-posting", "system": "http://hl7.org/fhir/research-study-registration-activity", "display": "Update posting"}]}}, {"url": "actual", "valueBoolean": true}, {"url": "period", "valuePeriod": {"end": "2019-10-08"}}]}, {"url": "http://hl7.org/fhir/StructureDefinition/artifact-author", "valueContactDetail": {"name": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}}], "objective": [{"type": {"coding": [{"code": "primary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Primary"}]}, "outcomeMeasure": [{"name": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia", "type": {"coding": [{"code": "primary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Primary"}]}, "endpoint": {"type": "EvidenceVariable", "display": "Percentage of Participants Achieving Treatment Success During Controlled Insulin-Induced Hypoglycemia", "reference": "EvidenceVariable/267226", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-primaryOutcome-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "Percentage of participants who achieved treatment success during the controlled insulin-induced hypoglycemia in participants with type 1 diabetes mellitus (T1DM) and participants with type 2 diabetes mellitus (T2DM).Treatment success is defined as an increase in plasma glucose to greater than or equal to (\u2265) 70 milligrams per deciliter (mg/dL) or an increase of \u226520 mg/dL from plasma glucose nadir, without receiving additional actions to increase the plasma glucose concentration. Nadir is defined as the minimum plasma glucose concentration at the time of or within 10 minutes following glucagon administration."}]}, {"type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "outcomeMeasure": [{"name": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM)", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "display": "Pharmacodynamics (PD): Change From Baseline in Maximal Blood Glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride Intramuscular (IM)", "reference": "EvidenceVariable/267227", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcome-0", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "PD assessment measured the change from Baseline in maximal blood glucose (BGmax) of Glucagon Nasal Powder and Glucagon Hydrochloride intramuscular (IM)."}, {"name": "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "display": "PD: Time to Maximal Concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM", "reference": "EvidenceVariable/267228", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcome-1", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "PD assessment measured the time to maximal concentration (Tmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM."}, {"name": "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "display": "Pharmacokinetics (PK): Change From Baseline in Area Under the Concentration Versus Time Curve From Zero to Time t (AUC [0-tLast]) of Glucagon Nasal Powder and Glucagon Hydrochloride IM", "reference": "EvidenceVariable/267229", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcome-2", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "PK assessment measured the change from baseline in the area under the concentration versus time curve from time zero to time t, where t is the last time point with a measurable concentration of Glucagon Nasal Powder and Glucagon Hydrochloride IM."}, {"name": "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "display": "PK: Change From Baseline in Maximal Concentration (Cmax) of Glucagon Nasal Powder and Glucagon Hydrochloride IM", "reference": "EvidenceVariable/267230", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcome-3", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "PK assessment measured the change from baseline in maximal concentration (Cmax) of glucagon nasal powder and glucagon hydrochloride IM."}, {"name": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM", "type": {"coding": [{"code": "secondary", "system": "http://terminology.hl7.org/CodeSystem/research-study-objective-type", "display": "Secondary"}]}, "endpoint": {"type": "EvidenceVariable", "display": "PK: Change From Baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM", "reference": "EvidenceVariable/267231", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379-secondaryOutcome-4", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "description": "PK assessment measured the change from baseline in Tmax of Glucagon Nasal Powder and Glucagon Hydrochloride IM."}]}], "relatesTo": [{"type": "transforms", "targetUri": "https://clinicaltrials.gov/api/v2/studies/NCT03421379?format=json"}, {"type": "transformed-with", "targetAttachment": {"url": "https://fevir.net/ctgovconvert", "title": "Computable Publishing\u00ae: ClinicalTrials.gov-to-FEvIR Converter"}}, {"type": "cites", "targetReference": {"type": "Citation", "display": "Seaquist E, Gimenez M, Yan Y, Matsuhisa M, Kao CY, Wadwa RP, Nagai Y, Khunti K. Nasal Glucagon Reverses Insulin-induced Hypoglycemia With Less Rebound Hyperglycemia: Pooled Analysis of Clinical Trials. J Endocr Soc. 2024 Feb 26;8(4):bvae034. doi: 10.1210/jendso/bvae034. eCollection 2024 Feb 19.", "identifier": {"value": "38444629", "system": "https://pubmed.ncbi.nlm.nih.gov"}}}, {"type": "supported-with", "targetAttachment": {"url": "https://www.clinicalstudydatarequest.com", "title": "IPD Sharing URL"}}, {"type": "documentation", "targetAttachment": {"url": "https://cdn.clinicaltrials.gov/large-docs/79/NCT03421379/Prot_000.pdf", "size": "684592", "title": "ProtStudy Protocol", "creation": "2017-12-05", "contentType": "application/pdf"}}, {"type": "documentation", "targetAttachment": {"url": "https://cdn.clinicaltrials.gov/large-docs/79/NCT03421379/SAP_001.pdf", "size": "444216", "title": "SAPStatistical Analysis Plan", "creation": "2018-02-02", "contentType": "application/pdf"}}], "classifier": [{"text": "IPDSharing: Yes"}, {"text": "IPDSharingDescription: Anonymized individual patient level data will be provided in a secure access environment upon approval of a research proposal and a signed data sharing agreement."}, {"text": "IPDSharingInfoType: Study Protocol"}, {"text": "IPDSharingInfoType: Statistical Analysis Plan (SAP)"}, {"text": "IPDSharingInfoType: Clinical Study Report (CSR)"}, {"text": "IPDSharingTimeFrame: Data are available 6 months after the primary publication and approval of the indication studied in the US and European Union (EU), whichever is later. Data will be indefinitely available for requesting."}, {"text": "IPDSharingAccessCriteria: A research proposal must be approved by an independent review panel and researchers must sign a data sharing agreement."}, {"text": "Does Not Accept Healthy Volunteers"}, {"text": "Minimum Age: 18 Years"}, {"text": "Maximum Age: 70 Years"}, {"text": "Age Group: Adult"}, {"text": "Age Group: Older Adult"}, {"text": "Has Results: True"}, {"text": "Oversight Classifier: oversightHasDmc False"}, {"text": "Oversight Classifier: isFdaRegulatedDrug True"}, {"text": "Oversight Classifier: isFdaRegulatedDevice False"}, {"text": "Oversight Classifier: isUsExport True"}, {"text": "AgreementPISponsorEmployee: False"}, {"text": "AgreementRestrictionType: GT60"}, {"text": "AgreementRestrictiveAgreement: True"}], "identifier": [{"type": {"text": "FEvIR Object Identifier", "coding": [{"code": "ACSN", "system": "http://terminology.hl7.org/CodeSystem/v2-0203", "display": "Accession ID"}]}, "value": "267223", "system": "https://fevir.net/FOI", "assigner": {"display": "Computable Publishing LLC"}}, {"use": "official", "value": "NCT03421379", "system": "https://clinicaltrials.gov"}, {"value": "16962", "assigner": {"display": "Eli Lilly and Company"}}, {"type": {"text": ["Other Identifier"]}, "value": "I8R-JE-IGBJ", "assigner": {"display": "Eli Lilly and Company"}}, {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379 FHIR Transform", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}], "recruitment": {"eligibility": {"type": "Group", "display": "NCT03421379 Eligibility Criteria", "reference": "Group/267225", "identifier": {"type": {"text": "FEvIR Linking Identifier"}, "value": "NCT03421379 Eligibility Criteria", "system": "https://fevir.net/FLI", "assigner": {"display": "Computable Publishing LLC"}}}, "actualNumber": 75}, "studyDesign": [{"text": "Design Masking: None (Open Label)"}, {"coding": [{"code": "SEVCO:01003", "system": "https://fevir.net/sevco", "display": "randomized assignment"}]}, {"coding": [{"code": "SEVCO:01012", "system": "https://fevir.net/sevco", "display": "Crossover cohort design"}]}, {"coding": [{"code": "SEVCO:01001", "system": "https://fevir.net/sevco", "display": "interventional research"}]}], "resourceType": "ResearchStudy", "progressStatus": [{"state": {"coding": [{"code": "completed", "system": "http://terminology.hl7.org/CodeSystem/research-study-status", "display": "Completed"}]}}, {"state": {"coding": [{"code": "overall-study", "system": "http://terminology.hl7.org/CodeSystem/research-study-status", "display": "Overall study"}]}, "actual": true, "period": {"end": "2018-08-20", "start": "2018-02-21"}}], "associatedParty": [{"name": "Eli Lilly and Company", "role": {"coding": [{"code": "sponsor", "system": "http://terminology.hl7.org/CodeSystem/research-study-party-role", "display": "Sponsor"}]}, "classifier": [{"text": "INDUSTRY"}]}, {"name": "Eli Lilly and Company", "role": {"coding": [{"code": "lead-sponsor", "system": "http://terminology.hl7.org/CodeSystem/research-study-party-role", "display": "Lead sponsor"}]}, "classifier": [{"text": "INDUSTRY"}]}, {"name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", "role": {"coding": [{"code": "study-chair", "system": "http://terminology.hl7.org/CodeSystem/research-study-party-role", "display": "Study chair"}]}, "party": {"display": "Eli Lilly and Company"}}], "comparisonGroup": [{"eligibility": {"type": "Group", "display": "Glucagon Nasal Powder: A single dose of 3 milligram (mg) glucagon nasal powder administered intranasally.", "reference": "#NCT03421379-comparison-group-0"}}, {"eligibility": {"type": "Group", "display": "Glucagon Hydrochloride Solution: A single dose of 1 mg glucagon hydrochloride solution was administered intramuscular (IM)", "reference": "#NCT03421379-comparison-group-1"}}], "descriptionSummary": "The purpose of this study is to determine the efficacy and safety of nasal glucagon compared to intramuscular (IM) glucagon for treatment of insulin-induced hypoglycemia in Japanese participants with diabetes mellitus.", "primaryPurposeType": {"coding": [{"code": "treatment", "system": "http://terminology.hl7.org/CodeSystem/research-study-prim-purp-type", "display": "Treatment"}]}}